^
    Back
    Association details:
    Biomarker:MET N375S
    Cancer:Salivary Gland Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    pazopanib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Onco Targets Ther
    Title:

    A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

    Published date:
    05/07/2021
    Excerpt:
    This is a single institution, open-label, phase I dose-escalation study in patients with advanced malignancies (NCT 01548144)….one patient with salivary gland tumor and MET p.N375S mutation had a best response of SD ≥6 months on dose level 5.
    DOI:
    10.2147/OTT.S291801
    Trial ID:
    NCT01548144